 Skye Bioscience inc OTCQB:SKYE has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion, a patented drug representing a new class of therapeutics to potentially treat glaucoma, from the Australian Human Research Ethics Committee HREC. The company said the primary endpoints for this randomized, double-masked, placebo-controlled Phase 1 study of SBI-100 OE are an assessment of safety and tolerability of the drug in healthy volunteers while the secondary endpoint is an assessment of pharmacokinetics. 